Can a targeted drug plus hormone therapy stop breast Cancer's return?

NCT ID NCT03820830

Ongoing Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 16, 2026 · Updated 11 times

Summary

This phase 3 trial tests whether adding palbociclib (Ibrance) to standard hormone therapy can delay breast cancer from returning in people whose cancer has come back in the same area. About 405 participants who have had surgery for their recurrence will receive either hormone therapy alone or hormone therapy plus palbociclib for 3 years. The study compares how long it takes for the cancer to return or for a new cancer to develop.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AOU Maggiore Della Carita, University of Eastern Piedmont

Novara, Italy
ASST Papa Giovanni XXIII

Bergamo, Italy
Azienda Ospedaliero-Universitaria di Parma

Parma, Italy
BZ Bethanien

Zurich, 8001, Switzerland
Brust-Zentrum AG Zürich

Zurich, Switzerland
Brustzentrum Basel Bethesda Spital

Basel, Switzerland
Centre Antoine Lacassagne

Nice, 06189, France
Centre Francois Baclesse

Caen, 14000, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Hospitalier Universitaire de Limoges

Limoges, 87000, France
Centre Leon Berard

Lyon, 69008, France
Centre Paul Strauss

Strasbourg, France
Centre du Sein Fribourg

Fribourg, Switzerland
Cro Irccs

Aviano, Italy
Cêntre Hospitaler de Cholet

Cholet, 49300, France
Fondazione Oncologia Lago Maggiore

Locarno, Switzerland
Groupe hospitalier de Bretagne Sud, Hôpital du Scorff

Lorient, France
Gustave Roussy

Villejuif, 94800, France
HU Ramón y Cajal

Madrid, Spain
Hospital General Universitario de Alicante

Alicante, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario Miguel Servet

Zaragoza, Spain
Hospital Universitario Río Hortega

Valladolid, Spain
Hospital Universitario Vall d´Hebrón

Barcelona, Spain
Hospital Universitario de Canarias

San Cristóbal de La Laguna, Tenerife, Spain
Hospital Universitario de La Coruña

A Coruña, Spain
Hospital Virgen de la Macarena

Seville, Spain
Hospital Virgen de la Victoria

Málaga, Spain
Hospital de Basurto

Bilbao, Spain
ICM Val d'Aurelle

Montpellier, 34298, France
Inselspital Bern

Bern, Switzerland
Institut Bergonie

Bordeaux, 33076, France
Institut Català d´Oncología (ICO)

Girona, Spain
Institut Claudius Regaud

Toulouse, 31100, France
Institut Sainte Catherine

Avignon, 84918, France
Instituto Catalan de Oncologia L´Hospitalet

Barcelona, Spain
Instituto Valenciano de Oncología (IVO)

Valencia, Spain
Istituti Clinici Scientifici Maugeri

Pavia, Italy
Istituto Europeo di Oncologia

Milan, Italy
Istituto scientifico Romagnolo per lo studio e la cura

Meldola, Italy
Kantonsspital Baden

Baden, Switzerland
Kantonsspital Winterthur

Winterthur, Switzerland
Kouros Moccia Oncologia

Locarno, Switzerland
Luzerner Kantonsspital

Lucerne, Switzerland
MUW - Universitätsklinik für Innere Medizin

Vienna, Austria
Medizinische Universität Graz (MUG)

Graz, Austria
Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde

Innsbruck, Austria
National Institute of Oncology

Budapest, Hungary
Ospedale S. Stefano

Prato, Italy
PO Antonio Perrino Brindisi

Brindisi, Italy
Polyclinique Bordeaux Nord

Bordeaux, 333000, France
U.O. Oncologia, Ospedale Infermi

Rimini, Italy
Uniklinikum Salzburg

Salzburg, Austria

Conditions

Explore the condition pages connected to this study.

BREAST CANCER RECURRENT